Download PDF
CC BY 4.0 · World J Nucl Med 2023; 22(04): 257-260
DOI: 10.1055/s-0043-1774419
Original Article

How Radioactive Iodine Treatment Affects the Retina

Ceren Gürez 
1   Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Health of Sciences University, Turkey
,
Aynur Özen 
2   Nuclear Medicine Clinic, Bagcilar Training and Research Hospital, Health of Sciences University, Turkey
,
Özgül Ekmekçioğlu 
3   Nuclear Medicine Clinic, Sisli Hamidiye Etfal Training and Research Hospital, Health of Sciences University, Turkey
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective The aim of this study was to quantitatively assess the macular and retinal nerve fiber layer thicknesses in patients with hyperthyroidism and thyroid cancer undergoing radioactive iodine (RAI) therapy.

Study Design This prospective study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Bagcilar Training and Research Hospital Clinical Research Ethics Committee. Written informed consent was obtained from the patients following a detailed explanation of the study objectives and protocol. Patient selection was randomized. Patients scheduled for RAI treatment in the Nuclear Medicine Clinic were referred to the ophthalmology clinic, respectively. Patients without additional ocular pathology were included in the study.

Methods All patients had received RAI therapy using Iodine-131 for hyperthyroidism or thyroid cancer. A complete ophthalmological examination and measurement of macular and retinal nerve fiber layer thickness using optical coherence tomography were performed on all patients before and at the first and sixth months and in first year after RAI treatment. The results were prospectively evaluated.

Results The study included 80 eyes of 40 patients. The hyperthyroid group was group 1, and the thyroid cancer group was group 2. There were 25 patients in group 1 and 15 patients in group 2. The mean age was 43.76 ± 11.85 years (range: 22–65 years) in group 1 and 39.87 ± 9.13 years (range: 30–58 years) in group 2. There was no significant difference between the two groups regarding age and sex (p > 0.05). In both groups, no significant difference was found in the macular thickness and retinal nerve fiber layer thicknesses values obtained in both eyes before and after the RAI treatment.

Conclusion As a result of our study, we observed that RAI intake did not harm the retinal layer.

Keywords

Macula - nerve fiber layer - radioactive iodine - thyroid cancer - hyperthyroidism

Authors' Contribution

Ceren Gürez was involved in patient selection, data collection, and writing. Aynur Özen and Özgül Ekmekçioğlu helped in patient selection and data collection.


Ethical Approval

The study was reviewed and approved by the Bagcilar Training and Research Hospital Ethics Committee with the 2014-319 registration number by principles of the Declaration of Helsinki and, written informed consent was obtained from all patients.




Publication History

Article published online:
04 December 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Silberstein EB, Alavi A, Balon HR. et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0.131 . J Nucl Med 2012; 53 (10) 1633-1651
    CrossrefPubMedGoogle Scholar
  • 2 Cooper DS, Doherty GM, Haugen BR. et al; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19 (11) 1167-1214
    CrossrefPubMedGoogle Scholar
  • 3 Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154 (06) 787-803
    CrossrefPubMedGoogle Scholar
  • 4 Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer.131 . Thyroid 2009; 19 (12) 1381-1391
    CrossrefPubMedGoogle Scholar
  • 5 Haugen BR. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. J Clin Endocrinol Metab 2004; 89 (08) 3665-3667
    CrossrefPubMedGoogle Scholar
  • 6 Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89 (08) 3668-3676
    CrossrefPubMedGoogle Scholar
  • 7 Fard-Esfahani A, Emami-Ardekani A, Fallahi B. et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun 2014; 35 (08) 808-817
    CrossrefPubMedGoogle Scholar
  • 8 Isgoren S, Daglioz Gorur G, Demir H, Berk F. Radioiodine therapy in Graves' disease: is it possible to predict outcome before therapy?. Nucl Med Commun 2012; 33 (08) 859-863
    CrossrefPubMedGoogle Scholar
  • 9 Tuttle RM, Becker DV, Hurley JR. Radioiodine treatment of thyroid diseases. In: Sandler MP, Coleman RE, Patton JA, Wackers FJ, Gottschalk A. eds. Diagnostic nuclear medicine. Philadelphia: Lippincott Williams & Wilkins; 2003: 653-670
    Google Scholar
  • 10 Bakheet SM, Hammami MM, Hemidan A, Powe JE, Bajaafar F. Radioiodine secretion in tears. J Nucl Med 1998; 39 (08) 1452-1454
    PubMedGoogle Scholar
  • 11 Zettinig G, Karanikas G, Hanselmayer G, Havlik E, Dudczak R. Radioactive contamination of contact lenses during radioiodine therapy. Nucl Med Commun 2000; 21 (10) 955-957
    CrossrefPubMedGoogle Scholar
  • 12 Aydogan F, Ayhan Tuzcu E, Aydogan A. et al. Effect of radioactive iodine therapy on lacrimal gland functions in patients with hyperthyroidism. Clin Nucl Med 2014; 39 (04) 315-318
    CrossrefPubMedGoogle Scholar
  • 13 Hee MR, Izatt JA, Swanson EA. et al. Optical coherence tomography of the human retina. Arch Ophthalmol 1995; 113 (03) 325-332
    CrossrefPubMedGoogle Scholar
  • 14 Schuman JS, Pedut-Kloizman T, Hertzmark E. et al. Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography. Ophthalmology 1996; 103 (11) 1889-1898
    CrossrefPubMedGoogle Scholar
  • 15 Paunescu LA, Schuman JS, Price LL. et al. Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using Stratus OCT. Invest Ophthalmol Vis Sci 2004; 45: 1716-1724
    CrossrefPubMedGoogle Scholar
  • 16 Clement SC, Peeters RP, Ronckers CM. et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma–a systematic review. Cancer Treat Rev. S0305–7372(15)00165–6
    Google Scholar
  • 17 Dreger S, Pfinder M, Christianson L, Lhachimi SK, Zeeb H. The effects of iodine blocking following nuclear accidents on thyroid cancer, hypothyroidism, and benign thyroid nodules: design of a systematic review. Syst Rev 2015; 4: 126
    CrossrefPubMedGoogle Scholar
  • 18 Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol 1999; 117 (02) 170-177
    CrossrefPubMedGoogle Scholar
  • 19 Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999; 117 (05) 609-614
    CrossrefPubMedGoogle Scholar
  • 20 Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 1999; 127 (05) 579-589
    CrossrefPubMedGoogle Scholar
  • 21 Puusaari I, Heikkonen J, Kivelä T. Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology 2004; 111 (09) 1768-1777
    CrossrefPubMedGoogle Scholar
  • 22 Kaçar Güveli T, Özkan S, Öner Tamam M. et al. The effect of high dose radioiodine therapy on formation of radiation retinopathy during thyroid cancer treatment. Mol Imaging Radionucl Ther 2014; 23 (03) 84-88
    CrossrefPubMedGoogle Scholar
  • 23 Hykin PG, Shields CL, Shields JA, Arevalo JF. The efficacy of focal laser therapy in radiation-induced macular edema. Ophthalmology 1998; 105 (08) 1425-1429
    CrossrefPubMedGoogle Scholar
  • 24 Kinyoun JL, Chittum ME, Wells CG. Photocoagulation treatment of radiation retinopathy. Am J Ophthalmol 1988; 105 (05) 470-478
    CrossrefPubMedGoogle Scholar
  • 25 Astrahan MA, Luxton G, Jozsef G, Liggett PE, Petrovich Z. Optimization of 125I ophthalmic plaque brachytherapy. Med Phys 1990; 17 (06) 1053-1057
    CrossrefPubMedGoogle Scholar
  • 26 Bechrakis NE, Bornfeld N, Zöller I, Foerster MH. Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology 2002; 109 (10) 1855-1861
    CrossrefPubMedGoogle Scholar
  • 27 Henk JM, Whitelocke RA, Warrington AP, Bessell EM. Radiation dose to the lens and cataract formation. Int J Radiat Oncol Biol Phys 1993; 25 (05) 815-820
    CrossrefPubMedGoogle Scholar
  • 28 Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol 2000; 84 (09) 1068-1070
    CrossrefPubMedGoogle Scholar